摘要
Objective:The present study aims to evaluate the in vivo efficacy of YINDARA-4 in improving the symptoms of irritable bowel syndrome(IBS)in a rat model and investigate the impact of YINDARA-4 on potential targets of IBS management,such as the serotonin level in intestinal tissues and the structure and composition of the gut microbiota.Methods:We developed an IBS rat model by combining stress from maternal separation,acetic acid administration,and restraint.We administered YINDARA-4 water extract to the IBS rat model for 10 consecutive days.The fecal water content,visceral sensitivity,gut microbiota,and serotonin levels in the colonic tissue were then analyzed and compared between the control group,IBS model group,and YINDARA-4–treated groups.Results:Treatment with YINDARA-4 reversed visceral hypersensitivity in a dose-dependent manner in the experimental rat model of IBS.The relief of visceral hypersensitivity upon treatment with YINDARA-4 involved regulation of the gut microbiota structure and composition,and normalization of elevated serotonin levels in the colon.The decrease in colonic serotonin levels with YINDARA-4 treatment might be associated with a reduction in the abundance of Helicobacter and enrichment of Butyricimonas.Conclusions:Treatment with YINDARA-4 was beneficial against visceral hypersensitivity in a rat model of IBS.The improved symptoms exhibited in IBS rats were associated with favorably altered gut microbiota and normalization of serotonin levels in the colon.
[目的]本研究旨在评估茵达日-4在大鼠动物模型中改善IBS症状的功效,并探究茵达日-4对如肠组织血清素水平和肠道菌群结构及组成等IBS潜在治疗靶点的影响。[方法]通过母子分离,醋酸灌肠和束缚应急复合造模方法构建IBS大鼠模型,利用茵达日-4水提物进行灌胃干预10天后,分析并比较对照组、模型组和干预组大鼠粪便含水量、内脏敏感性、肠道菌群和肠组织血清素水平等指标。[结果]茵达日-4干预可剂量依赖地逆转IBS模型鼠内脏超敏反应症状。其缓解内脏超敏反应的效果与肠道菌群结构和组成的调节,以及结肠中血清素水平异常升高的回调相关。茵达日-4治疗后结肠血清素水平的降低可能与Helicobacter属菌丰度的降低和Butyricimonas属菌的富集有关。[结论]茵达日-4对IBS模型鼠内脏超敏反应具有显著治疗效果。茵达日-4对肠道菌群和结肠中血清素水平的调节在模型鼠IBS症状缓解过程中发挥作用。
基金
funded by the foundation of the Key Laboratory of Ethnomedicine(Minzu University of China),the Ministry of Education(KLEM-ZZ201903,KLEM-ZZ2020GD01)
the Natural Science Foundation of Ningxia(2021AAC03358)
funded by the National Natural Science Foundation of China(81901682)
作者简介
Corresponding author:Lingpeng Pei,School of Pharmacy,Minzu University of China,Beijing 100081,China,E-mail:lppei@hotmail.com;Corresponding author:Enqi Wu,School of Pharmacy,Minzu University of China,Beijing 100081,China,E-mail:2012006@muc.edu.cn
